Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00811785 |
Menkes disease and occipital horn syndrome are two forms of copper deficiency that must be diagnosed and treated very early in life to prevent serious developmental problems. However, these and other forms of copper deficiency are not very well understood, and further research is needed to determine whether certain treatments are useful in treating copper deficiency. One such treatment is copper histidine, a copper replacement that can be injected directly into the body to avoid absorption through the gastrointestinal tract. This study will investigate the effectiveness, side effects, and dosage of copper histidine treatment for patients with copper deficiency. It will also collect medical history information from patients to allow researchers to study possible genetic and nongenetic origins of copper deficiency.
This study will include 50 subjects, all of whom will be children and adults who have been diagnosed with Menkes disease, occipital horn syndrome, or other unexplained copper deficiency.
Patients will receive a prescribed dose of copper histidine, which will be administered daily as an injection.
During the study, patients will be admitted to the NIH Clinical Center on an outpatient basis to evaluate their response to the copper histidine treatment. These evaluations will take place every 8 months, with a final evaluation performed after 3 years of treatment. During the outpatient visits, patients will be required to give blood and urine samples for testing and undergo ultrasound testing. They will also undergo brain MRI scans at the initial visit and at the 16-month and 36-month visits. Patients who agree will give additional blood samples for genetic research purposes.
Condition | Intervention | Phase |
---|---|---|
Menkes Disease Occipital Horn Syndrome Unexplained Copper Deficiency |
Drug: Copper Histidine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Efficacy Study |
Official Title: | Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency |
Estimated Enrollment: | 50 |
Study Start Date: | December 2008 |
Estimated Study Completion Date: | November 2013 |
Estimated Primary Completion Date: | November 2013 (Final data collection date for primary outcome measure) |
Menkes is a fatal genetic form of copper deficiency caused by mutations in a copper-transporting ATPase (ATP7A).
Pre-symptomatic diagnosis and therapy with copper injections is associated with improved overall survival and, based on their molecular defects, with vastly better neurological outcomes in some study is to further evaluate the relationship between specific molecular defects and clinical responses to early copper treatment in parenteral copper treatment in related genetic disorders, and in unexplained copper deficiency conditions, often associated with non-specific neurological abnormalities.
Ages Eligible for Study: | up to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Serum copper levels less than 75 micrograms/dl
EXCLUSION CRITERIA:
Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
Contact: TTY | 1-866-411-1010 |
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
Bethesda, Maryland, United States, 20892 |
Responsible Party: | National Institutes of Health ( Stephen G. Kaler, M.D./National Institute of Child Health and Human Development ) |
Study ID Numbers: | 090059, 09-CH-0059 |
Study First Received: | December 18, 2008 |
Last Updated: | August 24, 2009 |
ClinicalTrials.gov Identifier: | NCT00811785 History of Changes |
Health Authority: | United States: Federal Government |
Copper Deficiency Menkes Disease Neurodevelopment Occipital Horn Syndrome |
Ehlers-Danlos Syndrome Copper Neurodegenerative Diseases Brain Diseases Hemostatic Disorders Metabolism, Inborn Errors Occipital Horn Syndrome Heredodegenerative Disorders, Nervous System Hemorrhagic Disorders Connective Tissue Diseases Genetic Diseases, X-Linked Micronutrients Brain Diseases, Metabolic, Inborn Congenital Abnormalities Metabolic Disorder |
Neurobehavioral Manifestations Skin Diseases, Genetic Metabolic Diseases Collagen Diseases Skin Diseases Hematologic Diseases Blood Coagulation Disorders Menkes Syndrome Vascular Diseases Skin Abnormalities Central Nervous System Diseases Trace Elements Mental Retardation Genetic Diseases, Inborn Histidine |
Ehlers-Danlos Syndrome Physiological Effects of Drugs Copper Neurodegenerative Diseases Brain Diseases Hemostatic Disorders Metabolism, Inborn Errors Hemorrhagic Disorders Heredodegenerative Disorders, Nervous System Pathologic Processes Syndrome Connective Tissue Diseases Genetic Diseases, X-Linked Cardiovascular Diseases Micronutrients |
Brain Diseases, Metabolic, Inborn Congenital Abnormalities Skin Diseases, Genetic Neurobehavioral Manifestations Hair Diseases Metabolic Diseases Disease Collagen Diseases Skin Diseases Hematologic Diseases Growth Substances Nervous System Diseases Skin Abnormalities Vascular Diseases Central Nervous System Diseases |